Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative database
Not Applicable
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-jRCT1031220116
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd. Medical Affairs Division
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 11962
Inclusion Criteria
Patients with CRC aged over 20 years who were diagnosed between May 2014 and January 2021 by using the International Classification of Diseases, 10th revision (ICD-10) codes in the database.
-Patients who received FTD/TPI and/or regorafenib.
Exclusion Criteria
1) FTD/TPI- or regorafenib-treated patients with diseases other than CRC;
2) patients who received other chemotherapy except bevacizumab simultaneously with FTD/TPI
3) patients who received other chemotherapy simultaneously with regorafenib.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method time to treatment discontinuation, adverse events, post-treatment